Pilot study of high-dose mitoxantrone and busulfan plus autologous bone transplantation in patients with advanced malignancies

A. Khalil, N. Ciobanu, Joseph A. Sparano, Rasim A. Gucalp, J. P. Dutcher, P. H. Wiernik

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We performed a pilot trial of high-dose mitoxantrone 15 mg/m2 by i.v. infusion daily on days -6 to -4 and busulfan 1 mg/kg orally every 6 h (16 doses) on days -7 to -4 plus autologous bone marrow transplantation (BMT) in 10 patients with advanced cancer to determine the safety and feasibility of the combination. The median age of the study group was 42 years, all were women and all had progressed after prior chemotherapy (including doxorubicin in seven cases). Disease types included adenocarcinoma of the breast (n = 6) or ovary (n = 3), and non-Hodgkin's lymphoma (n = 1). The median time to an absolute neutrophil count ≥ 0.5 x 109/L and platelets ≥ 50 x 109/L were 16.5 and 28 days, respectively. There was a high degree of severe regimen-related toxicity, including severe mucositis (n = 7) and veno-occlusive disease (VOD) of the liver (n = 3). Three patients developed multisystem failure and died within 90 days of autologous BMT from complications related to VOD of the liver (n = 2) or septic shock (n = 1). We conclude that the dose and schedule of busulfan and mitoxantrone used in this study was associated with a high degree of unacceptable regimen-related toxicity.

Original languageEnglish (US)
Pages (from-to)93-97
Number of pages5
JournalBone Marrow Transplantation
Volume15
Issue number1
StatePublished - 1995

Fingerprint

Busulfan
Mitoxantrone
Bone Transplantation
Autologous Transplantation
Bone Marrow Transplantation
Liver Diseases
Mucositis
Septic Shock
Non-Hodgkin's Lymphoma
Doxorubicin
Ovary
Neoplasms
Appointments and Schedules
Adenocarcinoma
Breast
Neutrophils
Blood Platelets
Age Groups
Safety
Drug Therapy

Keywords

  • Busulfan
  • High-dose
  • Mitoxantrone

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Pilot study of high-dose mitoxantrone and busulfan plus autologous bone transplantation in patients with advanced malignancies. / Khalil, A.; Ciobanu, N.; Sparano, Joseph A.; Gucalp, Rasim A.; Dutcher, J. P.; Wiernik, P. H.

In: Bone Marrow Transplantation, Vol. 15, No. 1, 1995, p. 93-97.

Research output: Contribution to journalArticle

@article{1bf51a62b72c454c84c5c0c604bec252,
title = "Pilot study of high-dose mitoxantrone and busulfan plus autologous bone transplantation in patients with advanced malignancies",
abstract = "We performed a pilot trial of high-dose mitoxantrone 15 mg/m2 by i.v. infusion daily on days -6 to -4 and busulfan 1 mg/kg orally every 6 h (16 doses) on days -7 to -4 plus autologous bone marrow transplantation (BMT) in 10 patients with advanced cancer to determine the safety and feasibility of the combination. The median age of the study group was 42 years, all were women and all had progressed after prior chemotherapy (including doxorubicin in seven cases). Disease types included adenocarcinoma of the breast (n = 6) or ovary (n = 3), and non-Hodgkin's lymphoma (n = 1). The median time to an absolute neutrophil count ≥ 0.5 x 109/L and platelets ≥ 50 x 109/L were 16.5 and 28 days, respectively. There was a high degree of severe regimen-related toxicity, including severe mucositis (n = 7) and veno-occlusive disease (VOD) of the liver (n = 3). Three patients developed multisystem failure and died within 90 days of autologous BMT from complications related to VOD of the liver (n = 2) or septic shock (n = 1). We conclude that the dose and schedule of busulfan and mitoxantrone used in this study was associated with a high degree of unacceptable regimen-related toxicity.",
keywords = "Busulfan, High-dose, Mitoxantrone",
author = "A. Khalil and N. Ciobanu and Sparano, {Joseph A.} and Gucalp, {Rasim A.} and Dutcher, {J. P.} and Wiernik, {P. H.}",
year = "1995",
language = "English (US)",
volume = "15",
pages = "93--97",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Pilot study of high-dose mitoxantrone and busulfan plus autologous bone transplantation in patients with advanced malignancies

AU - Khalil, A.

AU - Ciobanu, N.

AU - Sparano, Joseph A.

AU - Gucalp, Rasim A.

AU - Dutcher, J. P.

AU - Wiernik, P. H.

PY - 1995

Y1 - 1995

N2 - We performed a pilot trial of high-dose mitoxantrone 15 mg/m2 by i.v. infusion daily on days -6 to -4 and busulfan 1 mg/kg orally every 6 h (16 doses) on days -7 to -4 plus autologous bone marrow transplantation (BMT) in 10 patients with advanced cancer to determine the safety and feasibility of the combination. The median age of the study group was 42 years, all were women and all had progressed after prior chemotherapy (including doxorubicin in seven cases). Disease types included adenocarcinoma of the breast (n = 6) or ovary (n = 3), and non-Hodgkin's lymphoma (n = 1). The median time to an absolute neutrophil count ≥ 0.5 x 109/L and platelets ≥ 50 x 109/L were 16.5 and 28 days, respectively. There was a high degree of severe regimen-related toxicity, including severe mucositis (n = 7) and veno-occlusive disease (VOD) of the liver (n = 3). Three patients developed multisystem failure and died within 90 days of autologous BMT from complications related to VOD of the liver (n = 2) or septic shock (n = 1). We conclude that the dose and schedule of busulfan and mitoxantrone used in this study was associated with a high degree of unacceptable regimen-related toxicity.

AB - We performed a pilot trial of high-dose mitoxantrone 15 mg/m2 by i.v. infusion daily on days -6 to -4 and busulfan 1 mg/kg orally every 6 h (16 doses) on days -7 to -4 plus autologous bone marrow transplantation (BMT) in 10 patients with advanced cancer to determine the safety and feasibility of the combination. The median age of the study group was 42 years, all were women and all had progressed after prior chemotherapy (including doxorubicin in seven cases). Disease types included adenocarcinoma of the breast (n = 6) or ovary (n = 3), and non-Hodgkin's lymphoma (n = 1). The median time to an absolute neutrophil count ≥ 0.5 x 109/L and platelets ≥ 50 x 109/L were 16.5 and 28 days, respectively. There was a high degree of severe regimen-related toxicity, including severe mucositis (n = 7) and veno-occlusive disease (VOD) of the liver (n = 3). Three patients developed multisystem failure and died within 90 days of autologous BMT from complications related to VOD of the liver (n = 2) or septic shock (n = 1). We conclude that the dose and schedule of busulfan and mitoxantrone used in this study was associated with a high degree of unacceptable regimen-related toxicity.

KW - Busulfan

KW - High-dose

KW - Mitoxantrone

UR - http://www.scopus.com/inward/record.url?scp=0028906556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028906556&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 93

EP - 97

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -